Re: Zum aktuellen Stand

Die Erneuerung oder Verlängerung ist auf gutem Wege bzw. wie in Fall von Moderna bereits erfolgt. Zum aktuellen Stand:
Comirnaty
Conditional marketing authorisation issued: 21/12/2020
Annual renewal application: under evaluation
COVID-19 Vaccine Janssen
Conditional marketing authorisation issued: 11/03/2021
Annual renewal application: under evaluation
Spikevax (previously COVID-19 Vaccine Moderna)
Conditional marketing authorisation issued: 06/01/2021
Annual renewal issued: 04/10/2021
Vaxzevria (previously COVID-19 Vaccine AstraZeneca) AstraZeneca AB
Conditional marketing authorisation issued: 29/01/2021
Annual renewal application: under evaluation